Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable

Hologic, Inc. (HOLX) and its subsidiary, Biotheranostics, recently presented new research findings. The results suggest that in the absence of Breast Cancer Index (BCI) genetic testing, a significant proportion of early-stage hormone receptor-positive (HR+) breast cancer survivors may have received excessive or insufficient treatment. The study was published in the March issue of the JNCCN — Journal of the National Comprehensive Cancer Network.Previous research has shown that most women with early-stage HR+ ...